Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate

FRANKFORT, Mich., May 11 /PRNewswire/ -- The following is being released today
by Howard E. Greene, Jr.

To my fellow shareholders:

As the founding CEO of Amylin and a board member for almost 22 years, I want
you to know how I plan to vote at our annual meeting.

In my opinion Amylin's talented employee team has created one of the best
product and technology platforms in the diabetes and obesity area. But,
shareholders have suffered because sales results have not reflected the
commercial potential of that platform.

I commend our present management team, under Dan Bradbury's leadership, for
recognizing that they need to achieve a more effective working relationship
with Lilly, and that they must design a more innovative strategy for
convincing primary care physicians that Amylin's injectible medicines are
their best treatment option for patients with diabetes.

Our board of directors will play a strategic role in meeting these challenges.
I believe management will have more freedom to think outside of the box if we
replace the directors most directly involved in crafting the disappointing
commercialization strategy.

Also, with the departures of Ginger Graham and me, the Amylin board loses more
than 60% of its stock ownership. I think our investors would be well served
by adding directors who directly represent large shareholdings.

So, I have decided to vote for the slate proposed by Eastbourne, including the
Icahn nominees.

Respectfully,

Howard E. Greene, Jr., Co-Founder of Amylin

SOURCE Howard E. Greene, Jr.

Howard E. Greene, Jr., hegreene@gmail.com, +1-212-858-1685 (email contact is
preferable)